Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine

Vaccine. 1992;10(9):614-6. doi: 10.1016/0264-410x(92)90442-m.


The reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine were evaluated after administration to 16 4-6-year-old children. The vaccine contained toxoided lymphocytosis-promoting factor (6.0 micrograms/dose), filamentous haemagglutinin (70 micrograms/dose), agglutinogens (1.4 micrograms/dose) and the 69 kDa protein (approximately 8.0 micrograms/dose). The vaccine was extremely well tolerated with few minor side effects following immunization. Significant increases in antibodies to all pertussis vaccine components were noted. In summary, this double-strength acellular pertussis vaccine, containing a very high dose of filamentous haemagglutinin, had minimal reactogenicity and was immunogenic. These findings, as well as other studies with this vaccine, indicate that filamentous haemagglutinin is not a major determinant of vaccine reactogenicity.

Publication types

  • Clinical Trial

MeSH terms

  • Antibodies, Bacterial / biosynthesis
  • Bordetella pertussis / immunology
  • Child
  • Child, Preschool
  • Female
  • Humans
  • Male
  • Pertussis Vaccine / adverse effects
  • Pertussis Vaccine / immunology
  • Pertussis Vaccine / isolation & purification*


  • Antibodies, Bacterial
  • Pertussis Vaccine